Wenhui Yu1, Shuzhong Duan2, Zaixue Yu3. 1. Department of Pharmacy, Affiliated Hospital of Chengde Medical University Chengde, Hebei, China. 2. Department of Nephrology, Affiliated Hospital of Chengde Medical University Chengde, Hebei, China. 3. Maternity and Child Health Hospital of Pingquan County Chengde, Hebei, China.
Abstract
OBJECTIVE: This study aimed to explore the efficacy of Bailing capsules combined with losartan to treat diabetic glomerulosclerosis (DG) and the combination's effect on blood and urine biochemistry. METHODS:160 DG patients admitted to our hospital were recruited as the study cohort and randomly divided into a control group and an observation group (n=80 in each group). The control group was treated with losartan, and the observation group was treated with losartan and Bailing capsules. The efficacy, diastolic blood pressure (DBP), systolic blood pressure (SBP), blood creatinine (Scr), 24 h urine protein (24 h UP), blood urea nitrogen (BUN), urine microalbumin (mALB), urine β2 microglobulin (β2-MG), glomerular filtration rates (GFR), TCM scores, serum superoxide dismutase (SOD), reactive oxygen species (ROS), 8-hydroxydeoxyguanine (8-OHdG), hypersensitive C-reactive protein (hs-CRP), transforming growth factor β1 (TGF-β1), and the serum amyloid A (SAA) levels were compared between the two groups. RESULTS: The overall effective rate was higher in the observation group (91.25%) than it was in the control group (78.75%) (P<0.05). After the treatment, the DBP, SBP, Scr, 24 h UP, BUN, mALB, and β2-MG levels were lower, and the GFR was higher in the observation group than in the control group (P<0.01). The TCM points were lower in the observation group than they were in the control group (P<0.01). The observation group also showed higher serum SOD and lower ROS, 8-OHdG, hs-CRP, TGF-β1, and SAA levels than the control group (P<0.01). The differences in the incidences of adverse reactions between the two groups were not significantly different (P>0.05). CONCLUSION: Bailing capsules combined with losartan in the treatment of diabetic glomerulosclerosis can improve the therapeutic efficacy, improve the blood and urine biochemical indexes, the renal function, and the clinical symptoms, reduce the oxidative stress, improve the microinflammatory state, and delay the progression of the disease without increasing the adverse reactions. AJTR
RCT Entities:
OBJECTIVE: This study aimed to explore the efficacy of Bailing capsules combined with losartan to treat diabetic glomerulosclerosis (DG) and the combination's effect on blood and urine biochemistry. METHODS: 160 DG patients admitted to our hospital were recruited as the study cohort and randomly divided into a control group and an observation group (n=80 in each group). The control group was treated with losartan, and the observation group was treated with losartan and Bailing capsules. The efficacy, diastolic blood pressure (DBP), systolic blood pressure (SBP), blood creatinine (Scr), 24 h urine protein (24 h UP), blood ureanitrogen (BUN), urine microalbumin (mALB), urine β2 microglobulin (β2-MG), glomerular filtration rates (GFR), TCM scores, serum superoxide dismutase (SOD), reactive oxygen species (ROS), 8-hydroxydeoxyguanine (8-OHdG), hypersensitiveC-reactive protein (hs-CRP), transforming growth factor β1 (TGF-β1), and the serum amyloid A (SAA) levels were compared between the two groups. RESULTS: The overall effective rate was higher in the observation group (91.25%) than it was in the control group (78.75%) (P<0.05). After the treatment, the DBP, SBP, Scr, 24 h UP, BUN, mALB, and β2-MG levels were lower, and the GFR was higher in the observation group than in the control group (P<0.01). The TCM points were lower in the observation group than they were in the control group (P<0.01). The observation group also showed higher serum SOD and lower ROS, 8-OHdG, hs-CRP, TGF-β1, and SAA levels than the control group (P<0.01). The differences in the incidences of adverse reactions between the two groups were not significantly different (P>0.05). CONCLUSION: Bailing capsules combined with losartan in the treatment of diabetic glomerulosclerosis can improve the therapeutic efficacy, improve the blood and urine biochemical indexes, the renal function, and the clinical symptoms, reduce the oxidative stress, improve the microinflammatory state, and delay the progression of the disease without increasing the adverse reactions. AJTR
Authors: Paweł Podgórski; Andrzej Konieczny; Łukasz Lis; Wojciech Witkiewicz; Zbigniew Hruby Journal: Adv Clin Exp Med Date: 2019-12 Impact factor: 1.727
Authors: Barend W Florijn; Jacques M G J Duijs; Johannes H Levels; Geesje M Dallinga-Thie; Yanan Wang; Anita N Boing; Yuana Yuana; Wendy Stam; Ronald W A L Limpens; Yu Wah Au; Rienk Nieuwland; Ton J Rabelink; Marlies E J Reinders; Anton Jan van Zonneveld; Roel Bijkerk Journal: Diabetes Date: 2019-09-10 Impact factor: 9.461